Newsmax TV & Webwww.newsmax.comFREE - In Google Play
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
Dr. Eva Cwynar, M.D.
Eva Cwynar, M.D., is a practicing endocrinologist, metabolic medicine specialist, and internist in Beverly Hills, Calif. She is an Assistant Clinical Professor of Medicine at UCLA, Dr. Cwynar provides state-of-the-art medical care for fatigue, metabolism, weight loss, and anti-aging. Her clients include both celebrities and everyday people. She has appeared on such TV shows as The Doctors, Dr. Phil, and Extra. Dr. Cwynar (www.DrEva.com) is world-renowned for her expertise in bio-identical hormone replacement, menopause, male menopause, thyroid function, weight loss, and overcoming fatigue. She has received numerous honors and awards, including California’s Doctor of the Year and Top Thyroid Doctor of Beverly Hills. Her new book is The Fatigue Solution (www.TheFatigueSolution.com).  

Tags: children | school | barron trump | task force | pandemic | covid-19

Trump 'Comfortable' Sending His Son Back to School


By    |   Wednesday, 22 July 2020 06:14 PM EDT

President Donald Trump is willing to put his son where his administration's policies are: Back in school in full this fall.

"I am comfortable with that," Trump told reporters at Wednesday's coronavirus task force briefing, when asked if he would be willing to send his son Barron back to school amid the rise in coronavirus cases. "We do have a national strategy, but as you know ultimately, it's up to the governors of the states.

"I think most governors, many governors want the schools to open. I would like to see the schools open, especially when you see statistics like this where we have great statistics on young people and on safety. We would like to see schools open. Want to see the economy open."

Also, Trump hailed his administration's deal to pay nearly $2 billion to buy enough of a COVID-19 vaccine being developed by Pfizer Inc and German biotech BioNTech SE to innoculate 50 million people if it proves to be safe and effective, the companies said Wednesday.

The contract for 100 million doses of the vaccine amounts to a $39 price tag for what is likely to be a two-dose course of treatment.

The contract is the most the United States has agreed to spend on a vaccine, although previous deals with other vaccine makers were intended to also help pay for development costs.

Pfizer and BioNTech will not receive any money from the government unless their vaccine succeeds in large clinical trials and can be successfully manufactured, according to a Pfizer spokeswoman.

Under the agreement, the government would also have an option to procure an additional 500 million doses. Pfizer said the price for the additional doses would be negotiated separately if the U.S. orders them.

The vaccine, if successful, will be made available to Americans at no cost, although their health insurance may be charged, the U.S. department of Health and Human Services (HHS) said.

Information from Reuters was used in this report.

© 2023 Newsmax. All rights reserved.

President Donald Trump put his son where his administration's policies are: Back in school in full this fall. "I am comfortable with that," Trump told reporters at Wednesday's coronavirus task force briefing.
children, school, barron trump, task force, pandemic, covid-19
Wednesday, 22 July 2020 06:14 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
Find Your Condition
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved
© Newsmax Media, Inc.
All Rights Reserved